bild

One of the buildings of the headquarters of Gilead Sciences, Inc. in Foster City, CA, on April 30, 2020. Its drug, Remdesivir, may be near regulatory authorization in the U.S. as a COVID-19 treatment following early data readouts for a pair of clinical trial. (KEYSTONE/LAIF/Frederic Neema)